Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 205

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment

Open access
Verrico, Christopher D., Miller, Gregory M., Madras, Bertha K. · 2006 · Psychopharmacology

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00213-005-0174-5

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 87

  1. Battaglia G, Brooks BP, Kulsakdinun C, De Souza EB (1988) Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol 149:159–163 · DOI · Paper page
  2. Berger UV, Gu XF, Azmitia EC (1992) The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine. Eur J Pharmacol 215:153–160 · DOI · Paper page
  3. Berry MD (2004) Mammalian central nervous system trace amines. Pharmacologic amphetamines, physiologic neuromodulators. J Neurochem 90(2):257–271 · DOI · Paper page
  4. Borowsky B, Adham N, Jones KA, Raddatz R, Artymyshyn R, Ogozalek KL, Durkin MM, Lakhlani PP, Bonini JA, Pathirana S, Boyle N, Pu X, Kouranova E, Lichtblau H, Ochoa FY, Branchek TA, Gerald C (2001) Trace amines: identification of a family of mammalian G protein-coupled receptors. Proc Natl Acad Sci U S A 98:8966–8971 · DOI · Paper page
  5. Bowyer JF, Young JF, Slikker W, Itzak Y, Mayorga AJ, Newport GD, Ali SF, Frederick DL, Paule MG (2003) Plasma levels of parent compound and metabolites after doses of either d-fenfluramine or d-3,4-methylenedioxymethamphetamine (MDMA) that produce long-term serotonergic alterations. Neurotoxicology 24:379–390 · DOI
  6. Buchert R, Thomasius R, Wilke F, Petersen K, Nebeling B, Obrocki J, Schulze O, Schmidt U, Clausen M (2004) A voxel-based PET investigation of the long-term effects of “Ecstasy” consumption on brain serotonin transporters. Am J Psychiatry 161:1181–1189 · DOI
  7. Bunzow JR, Sonders MS, Arttamangkul S, Harrison LM, Zhang G, Quigley DI, Darland T, Suchland KL, Pasumamula S, Kennedy JL, Olson SB, Magenis RE, Amara SG, Grandy DK (2001) Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol 60:1181–1188 · DOI · Paper page
  8. Check E (2004) Psychedelic drugs: the ups and downs of ecstasy. Nature 429:126–128 · DOI
  9. Colado MI, O'Shea E, Green AR (2004) Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function. Psychopharmacology (Berl) 173:249–263 · DOI
  10. Commins DL, Vosmer G, Virus RM, Woolverton WL, Schuster CR, Seiden LS (1987) Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther 241:338–345
  11. Dowling GP, McDonough ET III, Bost RO (1987) ‘Eve’ and ‘Ecstasy’. A report of five deaths associated with the use of MDEA and MDMA. JAMA 257:1615–1617 · DOI · Paper page
  12. Eshleman AJ, Neve RL, Janowsky A, Neve KA (1995) Characterization of a recombinant human dopamine transporter in multiple cell lines. J Pharmacol Exp Ther 274:276–283
  13. Eshleman AJ, Carmolli M, Cumbay M, Martens CR, Neve KA, Janowsky A (1999) Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type. J Pharmacol Exp Ther 289:877–885 · DOI · Paper page
  14. Fitzgerald JL, Reid JJ (1990) Effects of methylenedioxymethamphetamine on the release of monoamines from rat brain slices. Eur J Pharmacol 191:217–220 · DOI
  15. Fitzgerald JL, Reid JJ (1993) Interactions of methylenedioxymethamphetamine with monoamine transmitter release mechanisms in rat brain slices. Naunyn Schmiedebergs Arch Pharmacol 347:313–323 · DOI
  16. Fitzgerald JL, Reid JJ (1994) Sympathomimetic actions of methylenedioxymethamphetamine in rat and rabbit isolated cardiovascular tissues. J Pharm Pharmacol 46:826–832 · DOI
  17. Gehlert DR, Schmidt CJ, Wu L, Lovenberg W (1985) Evidence for specific methylenedioxymethamphetamine (Ecstasy) binding sites in the rat brain. Eur J Pharmacol 119:135–136 · doi:10.1016/0014-2999(85)90334-6
  18. Gordon CJ, Watkinson WP, O'Callaghan JP, Miller DB (1991) Effects of 3,4-methylenedioxymethamphetamine on autonomic thermoregulatory responses of the rat. Pharmacol Biochem Behav 38:339–344 · DOI · Paper page
  19. Gough B, Ali SF, Slikker W Jr, Holson RR (1991) Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on monoamines in rat caudate. Pharmacol Biochem Behav 39:619–623 · DOI
  20. Goulet M, Miller GM, Bendor J, Liu S, Meltzer PC, Madras BK (2001) Non-amines, drugs without an amine nitrogen, potently block serotonin transport: novel antidepressant candidates? Synapse 42:129–140 · DOI
  21. Gudelsky GA, Nash JF (1996) Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin–dopamine interactions. J Neurochem 66:243–249 · DOI · Paper page
  22. Hansen JP, Riddle EL, Sandoval V, Brown JM, Gibb JW, Hanson GR, Fleckenstein AE (2002) Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity. J Pharmacol Exp Ther 300:1093–1100 · DOI
  23. Harries DP, De Silva R (1992) ‘Ecstasy’ and intracerebral haemorrhage. Scott Med J 37:150–152 · DOI
  24. Hatzidimitriou G, McCann UD, Ricaurte GA (1999) Altered serotonin innervation patterns in the forebrain of monkeys treated with (±)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neurosci 19:5096–5107 · DOI · Paper page
  25. Hayner GN, McKinney H (1986) MDMA. The dark side of ecstasy. J Psychoactive Drugs 18:341–347 · DOI
  26. Jayanthi LD, Samuvel DJ, Ramamoorthy S (2004) Regulated internalization and phosphorylation of the native norepinephrine transporter in response to phorbol esters. Evidence for localization in lipid rafts and lipid raft-mediated internalization. J Biol Chem 279:19315–19326 · DOI
  27. Johnson MP, Hoffman AJ, Nichols DE (1986) Effects of the enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices. Eur J Pharmacol 132:269–276 · DOI · Paper page
  28. Johnson MP, Conarty PF, Nichols DE (1991) [3H]Monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues. Eur J Pharmacol 200:9–16 · DOI
  29. Kelly PA, Ritchie IM, Sangra M, Cursham MJ, Dickson EM, Kelly B, Neilson FP, Reidy MJ, Stevens MC (1994) Hyperaemia in rat neocortex produced by acute exposure to methylenedioxymethamphetamine. Brain Res 665:315–318 · DOI
  30. Khoshbouei H, Sen N, Guptaroy B, Johnson L, Lund D, Gnegy ME, Galli A, Javitch JA (2004) N-terminal phosphorylation of the dopamine transporter is required for amphetamine-induced efflux. PLoS Biol 2:E78 · DOI · Paper page
  31. Kish SJ (2002) How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy? Pharmacol Biochem Behav 71:845–855 · DOI
  32. Koch S, Galloway MP (1997) MDMA induced dopamine release in vivo: role of endogenous serotonin. J Neural Transm 104:135–46 · DOI · Paper page
  33. Lavelle A, Honner V, Docherty JR (1999) Investigation of the prejunctional alpha2-adrenoceptor mediated actions of MDMA in rat atrium and vas deferens. Br J Pharmacol 128:975–980 · DOI
  34. Logan BJ, Laverty R, Sanderson WD, Yee YB (1988) Differences between rats and mice in MDMA (methylenedioxymethylamphetamine) neurotoxicity. Eur J Pharmacol 152:227–234 · DOI
  35. Madras BK, Fahey MA, Bergman J, Canfield DR, Spealman RD (1989a) Effects of cocaine and related drugs in nonhuman primates. I. [3H]Cocaine binding sites in caudate–putamen. J Pharmacol Exp Ther 251:131–141
  36. Madras BK, Spealman RD, Fahey MA, Neumeyer JL, Saha JK, Milius RA (1989b) Cocaine receptors labeled by [3H]2β-cabomethoxy-3β-(4-fluorophenyl)tropane. Mol Pharmacol 36:518–524
  37. Madras BK, Jones AG, Mahmod A, Zimmerman RE, Garada B, Holman LB, Davison A, Blundell P, Meltzer PC (1996) Technepine: a high affinity 99m technetium probe to label the dopamine transporter in brain by SPECT imaging. Synapse 22:239–246 · DOI
  38. Madras BK, Verrico C, Jassen A, Miller GM (2004) Attention Deficit Hyperactivity Disorder (ADHD): new roles for old trace amines and monoamine transporters. Neuropsychopharmacology 29(Suppl. 1):S 137
  39. Mayerhofer A, Kovar KA, Schmidt WJ (2001) Changes in serotonin, dopamine and noradrenaline levels in striatum and nucleus accumbens after repeated administration of the abused drug MDMA in rats. Neurosci Lett 308:99–102 · DOI
  40. McCann UD, Ricaurte GA (2004) Amphetamine neurotoxicity: accomplishments and remaining challenges. Neurosci Biobehav Rev 27:821–826 · DOI
  41. McCann UD, Szabo Z, Seckin E, Rosenblatt P, Mathews WB, Ravert HT, Dannals RF, Ricaurte GA (2005) Quantitative PET Studies of the Serotonin Transporter in MDMA Users and Controls Using [(11)C]McN5652 and [(11)C]DASB. Neuropsychopharmacology 30(9):1741–1750. DOI 10.1038/sj.npp.1300736 · DOI · Paper page
  42. Mechan AO, Esteban B, O'Shea E, Elliott JM, Colado MI, Green AR (2002) The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) to rats. Br J Pharmacol 135:170–180 · DOI · Paper page
  43. Miller GM, Yatin SM, De La Garza R II, Goulet M, Madras BK (2001) Cloning of dopamine, norepinephrine and serotonin transporters from monkey brain: relevance to cocaine sensitivity. Brain Res Mol Brain Res 87:124–143 · DOI
  44. Miller GM, Verrico CD, Jassen AK, Konar M, Yang H, Panas HN, Bahn M, Johnson RS, Madras BK (2005) Primate trace amine receptor 1 modulation by the dopamine transporter. J Pharmacol Exp Ther 313(3):983–994. DOI 10.1124/jpet.105.084459 · DOI
  45. Mortensen OV, Kristensen AS, Rudnick G, Wiborg O (1999) Molecular cloning, expression and characterization of a bovine serotonin transporter. Brain Res Mol Brain Res 71:120–126 · DOI
  46. Nash JF, Brodkin J (1991) Microdialysis studies on 3,4-methylenedioxymethamphetamine-induced dopamine release: effect of dopamine uptake inhibitors. J Pharmacol Exp Ther 259:820–825
  47. Nash JF, Yamamoto BK (1992) Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3,4-methylenedioxymethamphetamine. Brain Res 581:237–243 · DOI · Paper page
  48. Nichols DE, Lloyd DH, Hoffman AJ, Nichols MB, Yim GK (1982) Effects of certain hallucinogenic amphetamine analogues on the release of [3H]serotonin from rat brain synaptosomes. J Med Chem 25:530–535 · DOI · Paper page
  49. O'Callaghan JP, Miller DB (1994) Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 270:741–751
  50. O'Shea E, Esteban B, Camarero J, Green AR, Colado MI (2001) Effect of GBR 12909 and fluoxetine on the acute and long term changes induced by MDMA (‘ecstasy’) on the 5-HT and dopamine concentrations in mouse brain. Neuropharmacology 40:65–74 · DOI
  51. Pacifici R, Pichini S, Zuccaro P, Farre M, Segura M, Ortuno J, Di Carlo S, Bacosi A, Roset PN, Segura J, de la Torre R (2004) Paroxetine inhibits acute effects of 3,4-methylenedioxymethamphetamine on the immune system in humans. J Pharmacol Exp Ther 309:285–292 · DOI
  52. Parrott AC (2001) Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research. Hum Psychopharmacol 16:557–577 · DOI · Paper page
  53. Ramamoorthy S, Blakely RD (1999) Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants. Science 285:763–766 · DOI · Paper page
  54. Ramamoorthy S, Giovanetti E, Qian Y, Blakely RD (1998) Phosphorylation and regulation of antidepressant-sensitive serotonin transporters. J Biol Chem 273:2458–2466 · DOI · Paper page
  55. Reneman L, Booij J, Habraken JB, De Bruin K, Hatzidimitriou G, Den Heeten GJ, Ricaurte GA (2002) Validity of [123I]beta-CIT SPECT in detecting MDMA-induced serotonergic neurotoxicity. Synapse 46:199–205 · DOI
  56. Ricaurte GA, McCann UD (1992) Neurotoxic amphetamine analogues: effects in monkeys and implications for humans. Ann N Y Acad Sci 648:371–382 · DOI
  57. Ricaurte GA, Forno LS, Wilson MA, DeLanney LE, Irwin I, Molliver ME, Langston JW (1988b) (±)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. JAMA 260:51–55 · DOI · Paper page
  58. Ricaurte GA, Martello AL, Katz JL, Martello MB (1992) Lasting effects of (±)-3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations. J Pharmacol Exp Ther 261:616–622
  59. Rothman RB, Baumann MH (2003) Monoamine transporters and psychostimulant drugs. Eur J Pharmacol 479:23–40 · DOI · Paper page
  60. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS (2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39:32–41 · DOI · Paper page
  61. Rudnick G, Wall SC (1992) The molecular mechanism of ‘ecstasy’ [3,4-methylenedioxymethamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci U S A 89:1817–1821 · DOI · Paper page
  62. Sanchez V, Camarero J, Esteban B, Peter MJ, Green AR, Colado MI (2001) The mechanisms involved in the long-lasting neuroprotective effect of fluoxetine against MDMA (‘ecstasy’)-induced degeneration of 5-HT nerve endings in rat brain. Br J Pharmacol 134:46–57 · DOI
  63. Sandoval V, Riddle EL, Ugarte YV, Hanson GR, Fleckenstein AE (2001) Methamphetamine-induced rapid and reversible changes in dopamine transporter function: an in vitro model. J Neurosci 21:1413–1419 · DOI
  64. Saunders C, Ferrer JV, Shi L, Chen J, Merrill G, Lamb ME, Leeb-Lundberg LM, Carvelli L, Javitch JA, Galli A (2000) Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. Proc Natl Acad Sci U S A 97:6850–6855 · DOI · Paper page
  65. Scheffel U, Szabo Z, Mathews WB, Finley PA, Dannals RF, Ravert HT, Szabo K, Yuan J, Ricaurte GA (1998) In vivo detection of short- and long-term MDMA neurotoxicity—a positron emission tomography study in the living baboon brain. Synapse 29:183–192 · DOI
  66. Shankaran M, Gudelsky GA (1998) Effect of 3,4-methylenedioxymethamphetamine (MDMA) on hippocampal dopamine and serotonin. Pharmacol Biochem Behav 61:361–366 · DOI
  67. Shankaran M, Yamamoto BK, Gudelsky GA (1999) Involvement of the serotonin transporter in the formation of hydroxyl radicals induced by 3,4-methylenedioxymethamphetamine. Eur J Pharmacol 385:103–110 · DOI
  68. Simantov R, Tauber M (1997) The abused drug MDMA (Ecstasy) induces programmed death of human serotonergic cells. FASEB J 11:141–146 · DOI
  69. Slikker W Jr, Ali SF, Scallet AC, Frith CH, Newport GD, Bailey JR (1988) Neurochemical and neurohistological alterations in the rat and monkey produced by orally administered methylenedioxymethamphetamine (MDMA). Toxicol Appl Pharmacol 94:448–457 · DOI
  70. Slikker W Jr, Holson RR, Ali SF, Kolta MG, Paule MG, Scallet AC, McMillan DE, Bailey JR, Hong JS, Scalzo FM (1989) Behavioral and neurochemical effects of orally administered MDMA in the rodent and nonhuman primate. Neurotoxicology 10:529–542
  71. Sonders MS, Zhu SJ, Zahniser NR, Kavanaugh MP, Amara SG (1997) Multiple ionic conductances of the human dopamine transporter: the actions of dopamine and psychostimulants. J Neurosci 17:960–974 · DOI · Paper page
  72. Sotnikova TD, Budygin EA, Jones SR, Dykstra LA, Caron MG, Gainetdinov RR (2004) Dopamine transporter-dependent and -independent actions of trace amine beta-phenylethylamine. J Neurochem 91(2):362–373 · DOI
  73. Steele TD, Nichols DE, Yim GK (1987) Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H]monoamines into synaptosomes from different regions of rat brain. Biochem Pharmacol 36:2297–2303 · DOI · Paper page
  74. Steele TD, Nichols DE, Yim GK (1989) MDMA transiently alters biogenic amines and metabolites in mouse brain and heart. Pharmacol Biochem Behav 34:223–227 · DOI
  75. Steele TD, McCann UD, Ricaurte GA (1994) 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”): pharmacology and toxicology in animals and humans. Addiction 89:539–551 · DOI · Paper page
  76. Taffe MA, Davis SA, Yuan J, Schroeder R, Hatzidimitriou G, Parsons LH, Ricaurte GA, Gold LH (2002) Cognitive performance of MDMA-treated rhesus monkeys: sensitivity to serotonergic challenge. Neuropsychopharmacology 27:993–1005 · DOI
  77. Taffe MA, Huitron-Resendiz S, Schroeder R, Parsons LH, Henriksen SJ, Gold LH (2003) MDMA exposure alters cognitive and electrophysiological sensitivity to rapid tryptophan depletion in rhesus monkeys. Pharmacol Biochem Behav 76:141–152 · DOI
  78. Thompson MR, Li KM, Clemens KJ, Gurtman CG, Hunt GE, Cornish JL, McGregor IS (2004) Chronic fluoxetine treatment partly attenuates the long-term anxiety and depressive symptoms induced by MDMA (‘Ecstasy’) in rats. Neuropsychopharmacology 29:694–704 · DOI
  79. Turner JJ, Parrott AC (2000) ‘Is MDMA a human neurotoxin?’: diverse views from the discussants. Neuropsychobiology 42:42–48 · DOI
  80. Wang SS, Ricaurte GA, Peroutka SJ (1987) [3H]3,4-Methylenedioxymethamphetamine (MDMA) interactions with brain membranes and glass fiber filter paper. Eur J Pharmacol 138:439–443 · doi:10.1016/0014-2999(87)90485-7
  81. White SR, Obradovic T, Imel KM, Wheaton MJ (1996) The effects of methylenedioxymethamphetamine (MDMA, “Ecstasy”) on monoaminergic neurotransmission in the central nervous system. Prog Neurobiol 49:455–479 · DOI · Paper page
  82. Xie T, Tong L, McCann UD, Yuan J, Becker KG, Mechan AO, Cheadle C, Donovan DM, Ricaurte GA (2004) Identification and characterization of metallothionein-1 and -2 gene expression in the context of (±)3,4-methylenedioxymethamphetamine-induced toxicity to brain dopaminergic neurons. J Neurosci 24:7043–7050 · DOI
  83. Yamamoto BK, Spanos LJ (1988) The acute effects of methylenedioxymethamphetamine on dopamine release in the awake-behaving rat. Eur J Pharmacol 148:195–203 · DOI · Paper page
  84. Yamamoto BK, Nash JF, Gudelsky GA (1995) Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra. J Pharmacol Exp Ther 273:1063–1070
  85. Yatin SM, Miller GM, Norton C, Madras BK (2002) Dopamine transporter-dependent induction of C-Fos in HEK cells. Synapse 45:52–65 · DOI
  86. Zaczek R, Hurt S, Culp S, De Souza EB (1989) Characterization of brain interactions with methylenedioxyamphetamine and methylenedioxymethamphetamine. NIDA Res Monogr 94:223–239
  87. Zaczek R, Culp S, De Souza EB (1990) Intrasynaptosomal sequestration of [3H]amphetamine and [3H]methylenedioxyamphetamine: characterization suggests the presence of a factor responsible for maintaining sequestration. J Neurochem 54:195–204 · DOI

Cited by

See all 205

Metadata

Authors
Verrico, C. D., Miller, G. M., & Madras, B. K.
Venue
Psychopharmacology
Published
2005-10-12
Volume
189
Issue
4
Pages
489-503
ISSN
  • 0033-3158 (ISSN-L)
  • 1432-2072
OpenAlex
W2007549333
Cited by
205
References
4
FWCI
1.92
Type
journal article
Language
en
Open access
bronze
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. https://app.cochat.ai/papers/10.1007/s00213-005-0174-5
The paper
Verrico, C. D., Miller, G. M., & Madras, B. K. (2006). MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology. https://doi.org/10.1007/s00213-005-0174-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.